http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 원상영 (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
이윤배,최정현,원상영 순천향대학교 부설 산업기술연구소 1997 순천향 산업기술연구소논문집 Vol.3 No.1
The plasticizer effect of poly(propylene carbonate) (PPC) on glass transition temperatures of po1y(vinyl chloride) (PVC) has been investigated and compared with dioctyl phthalate (DOP), a common plasticizer of PVC. The decrease in glass transition temperatures of the PPC blended PVC was not significant when compared with that of DOP. For the theoretical calculation of solubility parameters group molar attraction constants have been employed. The PPC performance was within an acceptable range for some type of application.
-
Pancreatic Endocrine Tumors: A Report on a Patient Treated with Sorafenib
정희경,노상영,홍숙희,원혜성,전은경,신옥란,이수림,고윤호 대한의학회 2011 Journal of Korean medical science Vol.26 No.7
A 31-yr-old man with abdominal pain was diagnosed with a pancreatic endocrine tumor and multiple hepatic metastases. Despite optimal treatment with interferon alpha, a somatostatin analog, local therapy with high-intensity focused ultrasound ablation for multiple hepatic metastases, and multiple lines of chemotherapy with etoposide/cisplatin combination chemotherapy and gemcitabine monotherapy, the tumor progressed. As few chemotherapeutic options were available for him, sorafenib (800 mg/day, daily) was administered as a salvage regimen. Sorafenib was continued despite two episodes of grade 3 skin toxicity; it delayed tumor progression compared to the previous immunotherapy and chemotherapy. Serial computed tomography scans showed that the primary and metastatic tumors were stable. Thirteen months after beginning targeted therapy, and up to the time of this report, the patient is well without disease progression. We suggest that sorafenib is effective against pancreatic endocrine tumors.
-
정찬권,홍숙희,노상영,고윤호,원혜성,이명아,우인숙,변재호,강진형,홍영선,김연실,주영훈,김민식 대한병리학회 2010 Journal of Pathology and Translational Medicine Vol.44 No.4
Background : Growing tumors adapt to a hypoxic environment and increase anaerobic glycolysis. This metabolic switch is related to aggressive behavior. We investigated the relationship between glycolytic metabolism biomarkers associated with hypoxia-inducible factor (HIF)-1α and prognosis. Methods : We performed immunohistochemical staining of HIF-1a, pyruvate dehydrogenase kinase (PDK) 1 and lactate dehydrogenase (LDH) 5 in 74 patients with oral squamous cell carcinoma (SCC) who had received curative radical resection. Results : High reactivity of HIF-1α, PDK 1 and LDH 5 was observed in 29 (39.2%), 32 (43.2%) and 54 (73.0%) patients, respectively. Expression levels of the three biomarkers were significantly correlated. All three markers were highly expressed in 16 (21.6%) patients. Elevated expression of the three markers was associated with increased invasiveness (p = 0.043) and recurrence (p = 0.017) of tumors. In survival analysis, upregulation of the three markers was additionally associated with shorter disease free survival (DFS, p = 0.001) and overall survival (OS, p = 0.002). High expression of all three markers was a strong independent prognostic factor for DFS (p = 0.030) and OS (p = 0.026). Conclusions : Oral SCC with altered glycolytic metabolism exhibits a more invasive and aggressive phenotype. Our results indicate that glycolytic metabolism biomarkers related to HIF-1α may be independent prognostic factors in patients with oral SCC.
-
전은경,홍숙희,김태희,정승은,박지찬,원혜성,고윤호,노상영,홍영선 대한암학회 2011 Cancer Research and Treatment Vol.43 No.3
Purpose The purpose of this study was to evaluate efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as second-line treatment after failure of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) for advanced gastric cancer. Materials and Methods Patients who received modified FOLFOX-4 as first-line treatment and then received sequential modified FOLFIRI for disease progression were included in this study. The modified FOLFIRI regimen consisted of irinotecan 150 mg/m2 in a 90-minute intravenous infusion on day 1, leucovorin (LV) 20 mg/m2 and 5-fluorouracil (5-FU) 400 mg/m2 as a bolus followed by 600 mg/m2 as a 22-hour infusion on days 1 and 2 with the same dose of 5-FU/LV of modified FOLFOX-4 every 2 weeks. Results A total of 32 patients received 126 courses of FOLFIRI chemotherapy. No complete response was achieved. Three patients (9.4%; 95% confidence interval [CI], 0 to 20.1%) achieved partial response, whereas 11 (34.4%; 95% CI, 17.0 to 51.8%) patients showed stable disease. Disease control rate (complete response, partial responses and stable diseases) was 43.8%(95% CI, 25.6 to 61.9%) and median follow up duration was 11.3 months (range, 2.23 to 37.9months). Median time to progression was 2 months (95% CI, 1.49 to 2.51 months), and median overall survival from the start of FOLFIRI was 5.84 months (95% CI, 4.34 to 7.34 months). Toxicities were tolerable. Conclusion Modified FOLFIRI as second-line chemotherapy after failure of the modified FOLFOX-4 in advanced gastric cancer was tolerable but showed a lower response rate. Further study about retrying 5-FU/LV with irinotecan after failure of the 5-FU/LV combined regimen is necessary in advanced gastric cancer.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
